MCID: ORL011
MIFTS: 60

Oral Cancer

Categories: Rare diseases, Cancer diseases, Oral diseases

Aliases & Classifications for Oral Cancer

MalaCards integrated aliases for Oral Cancer:

Name: Oral Cancer 49 36 51 40 3
Lip and Oral Cavity Carcinoma 69
Malignant Neoplasm of Mouth 69

Classifications:



External Ids:

KEGG 36 H00016

Summaries for Oral Cancer

MedlinePlus : 40 Oral cancer can form in any part of the mouth. Most oral cancers begin in the flat cells that cover the surfaces of your mouth, tongue, and lips. Anyone can get oral cancer, but the risk is higher if you are male, use tobacco, drink lots of alcohol, have HPV, or have a history of head or neck cancer. Frequent sun exposure is also a risk factor for lip cancer. Symptoms of oral cancer include White or red patches in your mouth A mouth sore that won't heal Bleeding in your mouth Loose teeth Problems or pain with swallowing A lump in your neck An earache Tests to diagnose oral cancer include a physical exam, endoscopy, biopsy, and imaging tests. Oral cancer treatments may include surgery, radiation therapy, and chemotherapy. Some patients have a combination of treatments. NIH: National Cancer Institute

MalaCards based summary : Oral Cancer, also known as lip and oral cavity carcinoma, is related to oral submucous fibrosis and tongue cancer, and has symptoms including snoring and halitosis. An important gene associated with Oral Cancer is ORAOV1 (Oral Cancer Overexpressed 1), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Endometrial cancer. The drugs Norepinephrine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, tongue and lung, and related phenotypes are cardiovascular system and growth/size/body region

NIH Rare Diseases : 49 Oral cancer includes cancers of the mouth, lips, and oropharynx (the part of the throat at the back of the mouth). Most cases are designated as squamous cell carcinomas because they begin in the flat cells (squamous cells) that cover the surfaces of the mouth, tongue, and lips. About 42,000 individuals in the United Stated are diagnosed with oral cancer each year. Most cases occur in people over age 40. Men are twice as likely to be affected as women. The use of alcohol and/or tobacco is associated with approximately 75 percent of oral cancers. Other risk factors include HPV, a sexually transmitted disease; increasing age; sun exposure; and a poor diet. Treatment for oral cancer may include surgery, radiation therapy, chemotherapy, or targeted therapy. Last updated: 6/21/2016

Wikipedia : 72 Oral cancer, also known as mouth cancer, is a type of head and neck cancer and is any cancerous tissue... more...

Related Diseases for Oral Cancer

Diseases related to Oral Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 208)
# Related Disease Score Top Affiliating Genes
1 oral submucous fibrosis 31.7 CDH1 CYP1A1 GSTM1 GSTT1 MMP2 PTGS2
2 tongue cancer 31.0 CCND1 CDH1 CDKN2A KRT13 MMP2 MMP9
3 leukoplakia 30.5 CYP1A1 GSTM1 GSTT1 KRT13
4 oral leukoplakia 30.5 CDKN2A GSTM1 GSTT1 TP53
5 mutagen sensitivity 29.9 CCND1 GSTM1 GSTT1 TP53
6 papilloma 29.7 CCND1 CDKN2A KRT13 TP53
7 salivary gland cancer 29.4 CASP3 EGFR MMP2 MMP9
8 b-cell lymphomas 29.4 CASP3 CCND1 CDKN2A TP53
9 squamous cell carcinoma 28.6 CCND1 CDH1 CDKN2A CYP1A1 EGFR KRT19
10 pharynx cancer 28.2 CASP3 CCND1 CDH1 CDKN2A EGFR GSTM1
11 cervical cancer 28.1 CASP3 CDKN2A GSTT1 KRT19 MMP2 PTGS2
12 prostate cancer 27.8 CASP3 CCND1 CDH1 EGFR GSTM1 MMP2
13 oral squamous cell carcinoma 27.8 CASP3 CCND1 CDH1 CDKN2A EGFR KRT13
14 lung cancer 26.7 CASP3 CCND1 CDH1 CDKN2A CYP1A1 EGFR
15 colorectal cancer 26.6 CASP3 CCND1 CDH1 CDKN2A CYP1A1 EGFR
16 oral lichen planus 11.1
17 geographic tongue 10.8
18 proliferative verrucous leukoplakia 10.8
19 hearing loss, noise-induced 10.6 GSTM1 GSTT1
20 brain ependymoma 10.6 EGFR TP53
21 brain stem astrocytic neoplasm 10.5 CDKN2A TP53
22 cerebral convexity meningioma 10.5 CDH1 TP53
23 extracranial arteriovenous malformation 10.5 MMP2 MMP9
24 breast papillomatosis 10.5 CCND1 CDKN2A
25 focal myositis 10.5 MMP2 MMP9
26 diffuse gastric cancer 10.5 CDH1 GSTM1 GSTT1
27 squamous cell carcinoma of the oropharynx 10.5 CDKN2A TP53
28 sister chromatid exchange, frequency of 10.5 GSTM1 GSTT1
29 protoplasmic astrocytoma 10.5 PTGS2 TP53
30 breast metaplastic carcinoma 10.5 CDH1 EGFR TP53
31 short-rib thoracic dysplasia 4 with or without polydactyly 10.4 CASP3 TP53
32 hidradenocarcinoma 10.4 CCND1 EGFR TP53
33 microcystic meningioma 10.4 CDH1 MMP2 MMP9
34 villous adenocarcinoma 10.4 EGFR MMP2 MMP9
35 malignant ovarian surface epithelial-stromal neoplasm 10.4 CDH1 MMP2 TP53
36 ovary epithelial cancer 10.4 CDH1 MMP2 TP53
37 lung giant cell carcinoma 10.4 CDH1 MMP2 MMP9
38 varicocele 10.4 CASP3 GSTM1 GSTT1
39 oropharynx cancer 10.4 CDKN2A EGFR TP53
40 clear cell renal cell carcinoma 10.4 CCND1 EGFR TP53
41 spastic entropion 10.4 MMP2 MMP9
42 tonsil squamous cell carcinoma 10.4 CCND1 CDKN2A
43 internal hemorrhoid 10.4 CASP3 MMP2 MMP9
44 estrogen-receptor positive breast cancer 10.4 CCND1 EGFR TP53
45 lentigo maligna melanoma 10.4 MMP2 MMP9
46 retinal cancer 10.4 CCND1 CDKN2A TP53
47 mucinous adenocarcinoma 10.4 CDKN2A EGFR TP53
48 sensory system cancer 10.4 CCND1 CDKN2A TP53
49 uterine carcinosarcoma 10.4 EGFR PTGS2 TP53
50 cholecystitis 10.4 CDH1 CDKN2A TP53

Graphical network of the top 20 diseases related to Oral Cancer:



Diseases related to Oral Cancer

Symptoms & Phenotypes for Oral Cancer

UMLS symptoms related to Oral Cancer:


snoring, halitosis

MGI Mouse Phenotypes related to Oral Cancer:

43 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.4 CCND1 ANO1 CASP3 CDH1 CYP1A1 EGFR
2 growth/size/body region MP:0005378 10.38 CDK2AP1 CCND1 ANO1 CASP3 CDH1 CYP1A1
3 mortality/aging MP:0010768 10.37 CCND1 ANO1 CASP3 CDH1 CYP1A1 KRT19
4 cellular MP:0005384 10.36 CASP3 CDH1 CCND1 CDK2AP1 EGFR CDKN2A
5 digestive/alimentary MP:0005381 10.27 CCND1 CASP3 CDH1 KRT19 EGFR CDKN2A
6 immune system MP:0005387 10.26 CASP3 CDH1 CCND1 CYP1A1 EGFR CDKN2A
7 endocrine/exocrine gland MP:0005379 10.25 CASP3 CDH1 CCND1 CYP1A1 EGFR CDKN2A
8 integument MP:0010771 10.21 CCND1 ANO1 CASP3 CDH1 KRT19 EGFR
9 nervous system MP:0003631 10.21 ANO1 CCND1 CASP3 EGFR CDKN2A KRT19
10 embryo MP:0005380 10.16 CDH1 CDKN2A CDK2AP1 EGFR PTGS2 KRT19
11 muscle MP:0005369 10.13 ANO1 CASP3 EGFR CDKN2A MMP9 MMP2
12 craniofacial MP:0005382 10.12 CASP3 CCND1 CDK2AP1 EGFR MMP2 TP53
13 neoplasm MP:0002006 10.11 CCND1 CDH1 KRT19 EGFR CDKN2A PTGS2
14 normal MP:0002873 10.02 CDH1 CCND1 CYP1A1 EGFR KRT19 MMP2
15 no phenotypic analysis MP:0003012 10.01 CASP3 CDH1 CYP1A1 EGFR CDKN2A KRT19
16 reproductive system MP:0005389 9.96 CDH1 CCND1 CASP3 KRT19 EGFR CDKN2A
17 renal/urinary system MP:0005367 9.87 CASP3 ANO1 EGFR PTGS2 MMP9 TP53
18 respiratory system MP:0005388 9.85 CCND1 ANO1 CASP3 EGFR CDKN2A MMP9
19 skeleton MP:0005390 9.73 CCND1 ANO1 CASP3 KRT19 EGFR CDKN2A
20 vision/eye MP:0005391 9.28 CCND1 CASP3 EGFR CDKN2A MMP9 MMP2

Drugs & Therapeutics for Oral Cancer

Drugs for Oral Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 324)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Norepinephrine Approved Phase 4 51-41-2 439260
2
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
3
Nicotine Approved Phase 4 54-11-5 89594 942
4
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 1 51-43-4 5816
5
Bupropion Approved Phase 4,Phase 2 34911-55-2, 34841-39-9 444
6
Dobutamine Approved Phase 4 34368-04-2 36811
7 Dopexamine Approved, Investigational Phase 4 86197-47-9 55483
8 Racepinephrine Approved Phase 4,Phase 2,Phase 1 329-65-7
9 Adrenergic Agents Phase 4,Phase 2,Phase 3
10 Adrenergic Agonists Phase 4,Phase 2,Phase 3
11 Adrenergic alpha-Agonists Phase 4,Phase 2,Phase 3
12 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Early Phase 1
13 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2
14 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
15 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
16 Liver Extracts Phase 4,Phase 2,Phase 1
17 Dopamine agonists Phase 4
18 Respiratory System Agents Phase 4
19 Central Nervous System Stimulants Phase 4
20 Mydriatics Phase 4
21 Adrenergic beta-Agonists Phase 4
22 Cholinergic Agents Phase 4,Phase 2,Phase 3
23 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
24 Nicotinic Agonists Phase 4
25 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
26 Vasoconstrictor Agents Phase 4,Phase 1,Phase 2
27 Vasodilator Agents Phase 4
28 Dopamine Agents Phase 4,Phase 2
29 Dopamine Uptake Inhibitors Phase 4,Phase 2
30 Anti-Asthmatic Agents Phase 4
31 Epinephryl borate Phase 4,Phase 2,Phase 1
32 Antidepressive Agents Phase 4,Phase 2
33 Antidepressive Agents, Second-Generation Phase 4,Phase 2
34 Psychotropic Drugs Phase 4,Phase 2
35 Autonomic Agents Phase 4,Phase 2,Phase 3
36 Bronchodilator Agents Phase 4
37
Ethanol Approved Phase 3,Early Phase 1 64-17-5 702
38
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
39
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
40
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
41
Celecoxib Approved, Investigational Phase 2, Phase 3,Phase 1 169590-42-5 2662
42
Dexmedetomidine Approved, Vet_approved Phase 2, Phase 3 76631-46-4, 113775-47-6 5311068 56032 68602
43
Cetuximab Approved Phase 2, Phase 3, Phase 1 205923-56-4 56842117 2333
44
Propofol Approved, Investigational, Vet_approved Phase 2, Phase 3 2078-54-8 4943
45
Aldesleukin Approved Phase 3 110942-02-4, 85898-30-2
46
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
47
Zinc Approved, Investigational Phase 2, Phase 3 7440-66-6 32051 23994
48
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
49
Pilocarpine Approved, Investigational Phase 2, Phase 3 92-13-7, 54-71-7 5910
50
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3

Interventional clinical trials:

(show top 50) (show all 408)

# Name Status NCT ID Phase Drugs
1 Diagnosis of Oral Precancers and Cancers Using Optic Coherence Tomography Unknown status NCT00172965 Phase 4
2 Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery Completed NCT01418118 Phase 4 Epinephrine;Norepinephrine;Dobutamine;Dopexamine
3 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
4 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
5 Photodynamic Therapy for Oral Leukoplakia and Erythroleukoplakia Completed NCT00155337 Phase 4
6 The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor Recruiting NCT03017053 Phase 4
7 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
8 Oral Cancer Screening in Mumbai, India by Primary Health Care Workers Unknown status NCT00655421 Phase 3
9 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
10 Oral Cancer Adjuvant Therapy (OCAT) Trial Unknown status NCT00193843 Phase 3
11 Trial of IIb Preserving Neck Dissection Unknown status NCT00847717 Phase 3
12 Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil
13 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
14 The Feasibility of Dexmedetomidine for Awake Fiberoptic Nasal Intubation Unknown status NCT00815893 Phase 2, Phase 3 dexmedetomidine;Normal Saline 0.9%;propofol 1%
15 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
16 Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors Unknown status NCT01216800 Phase 3
17 Workplace Tobacco Cessation And Oral Cancer Screening Study Completed NCT00750503 Phase 3
18 Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients Completed NCT00201383 Phase 3 cisplatin
19 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Completed NCT00004234 Phase 3
20 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01434394 Phase 2, Phase 3 Neo-adjuvant Erbitux-based chemotherapy
21 Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Completed NCT00158652 Phase 3 5FU, Paraplatin
22 Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
23 Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population Completed NCT00359645 Phase 3
24 Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma Completed NCT00201279 Phase 3 13-cis Retino Acid
25 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
26 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
27 The Use of Human Acellular Dermal Matrix to Improve Infraauricular Depressed Deformities and Frey's Syndrome Completed NCT01414790 Phase 3
28 Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis. Recruiting NCT00964977 Phase 3
29 Effect of Oral Vitamin C in Assessing the Severity of Oral Mucositis in Chemoradiation of Head and Neck Cancers Recruiting NCT02868151 Phase 2, Phase 3 Ascorbic Acid;Zinc acetate
30 Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer Recruiting NCT02048254 Phase 3
31 Erlotinib Prevention of Oral Cancer (EPOC) Active, not recruiting NCT00402779 Phase 3 Erlotinib;Placebo
32 IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC Active, not recruiting NCT00158678 Phase 3 concomitant cisplatin
33 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
34 Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer Active, not recruiting NCT01141231 Phase 3
35 Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
36 A Study of High-Risk Oral Cavity Cancer Terminated NCT00934739 Phase 2, Phase 3 Thalidomide, Celebrex;Cyclophosphamide, Dexamethasone
37 OraTest in Combination With Visual Examination and Visual Examination Alone Terminated NCT00537199 Phase 3 OraTest
38 S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat Terminated NCT00006994 Phase 3 l-glutamine placebo
39 Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer Terminated NCT00412776 Phase 2, Phase 3 Proxinium
40 Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence Withdrawn NCT01142414 Phase 3 cisplatin;fluorouracil
41 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx Unknown status NCT00004094 Phase 2 carboplatin;fluorouracil;hydroxyurea;paclitaxel
42 CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT Unknown status NCT01760811 Phase 1, Phase 2 Erbitux,merck serono
43 Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy Unknown status NCT02216916 Phase 2 HM781-36B
44 Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer Unknown status NCT01914900 Phase 2 docetaxel, cisplatin, 5 fluorouracil
45 Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00003777 Phase 2 amifostine trihydrate;cisplatin;fluorouracil
46 Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
47 Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
48 Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00003327 Phase 2 paclitaxel
49 Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia Unknown status NCT00052611 Phase 2 celecoxib
50 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir

Search NIH Clinical Center for Oral Cancer

Genetic Tests for Oral Cancer

Anatomical Context for Oral Cancer

MalaCards organs/tissues related to Oral Cancer:

38
Salivary Gland, Tongue, Lung, Testes, Breast, Lymph Node, Brain

Publications for Oral Cancer

Articles related to Oral Cancer:

(show top 50) (show all 1275)
# Title Authors Year
1
Investigation of cancer-associated fibroblasts and p62 expression in oral cancer before and after chemotherapy. ( 29439841 )
2018
2
Genetic and epigenetic alterations in the tumour, tumour margins, and normal buccal mucosa of patients with oral cancer. ( 29449053 )
2018
3
Stimuli-disassembling gold nanoclusters for diagnosis of early stage oral cancer by optical coherence tomography. ( 29399435 )
2018
4
A worldwide comparison of the management of surgical treatment of advanced oral cancer. ( 29395993 )
2018
5
Exploring determinants of care-seeking behaviour of oral cancer patients in India: A qualitative content analysis. ( 29438925 )
2018
6
Zerumbone targets the CXCR4-RhoA and PI3K-mTOR signaling axis to reduce motility and proliferation of oral cancer cells. ( 29433681 )
2018
7
Ultrasound-Guided Real-Time Pterygopalatine Block for Analgesia in an Oral Cancer Patient. ( 29440818 )
2018
8
Oridonin inhibits oral cancer growth and PI3K/Akt signaling pathway. ( 29432993 )
2018
9
Human papilloma virus: An etiological and prognostic factor for oral cancer? ( 29322686 )
2018
10
Monitoring of free flaps and reconstruction for oral cancer. ( 29398190 )
2018
11
Piperlongumine inhibits cancer stem cell properties and regulates multiple malignant phenotypes in oral cancer. ( 29399195 )
2018
12
Assessing Oral Cancer Awareness Among Dental Students. ( 29446005 )
2018
13
Quality of life after reconstruction with a free forearm flap in patients who have survived oral cancer for more than five years. ( 29395451 )
2018
14
Corrigendum to "Oral cancer-derived exosomal NAP1 enhances cytotoxicity of natural killer cells via the IRF-3 pathway" [Oral Oncol. 76 (2018) 34-41]. ( 29396179 )
2018
15
Circadian clock and oral cancer. ( 29435282 )
2018
16
Mitogen-activated protein kinase signaling pathway in oral cancer. ( 29434828 )
2018
17
Development and<i>in vitro</i>evaluation of mucoadhesive patches of methotrexate for targeted delivery in oral cancer. ( 29434971 )
2018
18
Awareness and Knowledge of Oral Cancer among Siamese Ethnic Group in Tumpat, Kelantan. ( 28951689 )
2017
19
Population-based screening program for reducing oral cancer mortality in 2,334,299 Taiwanese cigarette smokers and/or betel quid chewers. ( 28055109 )
2017
20
Survival after surgery for oral cancer: a 30-year experience. ( 28918183 )
2017
21
Study of the TP53 codon 72 polymorphism in oral cancer and oral potentially malignant disorders in Argentine patients. ( 28459200 )
2017
22
Interventions for treating oral leukoplakia to prevent oral cancer. ( 28537153 )
2017
23
Plasma levels of the tissue inhibitor matrix metalloproteinase-3 as a potential biomarker in oral cancer progression. ( 28138307 )
2017
24
Vimentin regulates differentiation switch via modulation of keratin 14 levels and their expression together correlates with poor prognosis in oral cancer patients. ( 28225793 )
2017
25
Combinations of SERPINB5 gene polymorphisms and environmental factors are associated with oral cancer risks. ( 28339463 )
2017
26
Positron Emission Tomographic Imaging Elucidates the Complex Relationship Between Glucose Uptake and Tissue Blood Flow Mechanism in Squamous Cell Oral Cancer Patients. ( 28934176 )
2017
27
Impacts of survivin and caspase-3 on apoptosis and angiogenesis in oral cancer. ( 28927146 )
2017
28
Cancer-associated fibroblasts regulate keratinocyte cell-cell adhesion via TGF-I^-dependent pathways in genotype-specific oral cancer. ( 27803052 )
2017
29
Single nucleotide polymorphisms in an Indian cohort and association of CNTN4, MMP2 and SNTB1 variants with oral cancer. ( 28595731 )
2017
30
EZH2-mediated upregulation of ROS1 oncogene promotes oral cancer metastasis. ( 28759046 )
2017
31
Iodinated chlorin p6 copper complex induces anti-proliferative effect in oral cancer cells through elevation of intracellular reactive oxygen species. ( 28918125 )
2017
32
Syngeneic Mouse Models of Oral Cancer are Effectively Targeted by anti-CD44-based NIR-PIT. ( 28923838 )
2017
33
Chemoprevention of oral cancer in leukoplakia patients: A systematic review and meta-analysis. ( 28924285 )
2017
34
May High MMP-2 and TIMP-2 Expressions Increase or Decrease the Aggressivity of Oral Cancer? ( 27853937 )
2017
35
Next-generation Sequencing for microRNA Profiling: MicroRNA-21-3p Promotes Oral Cancer Metastasis. ( 28314265 )
2017
36
Variations in oral microbiota associated with oral cancer. ( 28924229 )
2017
37
Development of oral cancer vaccine using recombinant Bifidobacterium displaying Wilms' tumor 1 protein. ( 28299466 )
2017
38
Assessment of the quality of life of the patients with treated oral cancer in Iran. ( 28948377 )
2017
39
Long noncoding RNA LncHIFCAR/MIR31HG is a HIF-1I+ co-activator driving oral cancer progression. ( 28639619 )
2017
40
Hypermethylation of IFN-I^ in oral cancer tissues. ( 28091876 )
2017
41
Screening and early detection of oral cancer: current controversies. ( 28937121 )
2017
42
Role of Monocyte Count and Neutrophil-to-Lymphocyte Ratio in Survival of Oral Cancer Patients. ( 28050203 )
2017
43
Withaferin A Induces Oxidative Stress-Mediated Apoptosis and DNA Damage in Oral Cancer Cells. ( 28936177 )
2017
44
Quantitative prediction of oral cancer risk in patients with oral leukoplakia. ( 28545021 )
2017
45
Nanoparticle delivery of Wnt-1 siRNA enhances photodynamic therapy by inhibiting epithelial-mesenchymal transition for oral cancer. ( 28070573 )
2017
46
Gender specific association of TP53 polymorphisms (EX4 215G>C Arg72Pro, IVS3+40-41ins16, and IVS6+62G>A), with risk of oral cancer subtypes and overall survival of the patients. ( 27532290 )
2017
47
Patient-reported quality of life outcomes following treatment for oral cancer. ( 28943022 )
2017
48
A facile gold nanoparticle-based ELISA system for detection of osteopontin in saliva: Towards oral cancer diagnostics. ( 28917507 )
2017
49
MiR-214 regulates oral cancer KB cell apoptosis through targeting RASSF5. ( 28290615 )
2017
50
In Vitro Growth of Human Keratinocytes and Oral Cancer Cells into Microtissues: An Aerosol-Based Microencapsulation Technique. ( 28952522 )
2017

Variations for Oral Cancer

Cosmic variations for Oral Cancer:

9 (show top 50) (show all 547)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM3724309 ZNF536 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1935G>C p.Q645H 7
2 COSM11181 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.764T>C p.I255T 7
3 COSM43565 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.857A>G p.E286G 7
4 COSM43695 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.748C>T p.P250S 7
5 COSM10786 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.949C>T p.Q317* 7
6 COSM44894 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.874A>T p.K292* 7
7 COSM43592 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.395A>T p.K132M 7
8 COSM45615 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.776A>G p.D259G 7
9 COSM10659 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.817C>T p.R273C 7
10 COSM11133 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.725G>C p.C242S 7
11 COSM10646 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.725G>A p.C242Y 7
12 COSM10662 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 7
13 COSM10724 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.839G>C p.R280T 7
14 COSM45248 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.805A>T p.S269C 7
15 COSM10727 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.438G>A p.W146* 7
16 COSM43606 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.734G>A p.G245D 7
17 COSM10988 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.772G>A p.E258K 7
18 COSM43635 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.536A>T p.H179L 7
19 COSM44350 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.699C>G p.H233Q 7
20 COSM11063 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.711G>T p.M237I 7
21 COSM11677 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.925C>T p.P309S 7
22 COSM11166 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.406C>T p.Q136* 7
23 COSM10859 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.814G>T p.V272L 7
24 COSM10958 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.797G>T p.G266V 7
25 COSM10758 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.659A>G p.Y220C 7
26 COSM44821 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.412G>A p.A138T 7
27 COSM44335 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.958A>T p.K320* 7
28 COSM43708 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.422G>A p.C141Y 7
29 COSM43947 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.614A>G p.Y205C 7
30 COSM45636 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.934A>T p.T312S 7
31 COSM11066 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.578A>T p.H193L 7
32 COSM43564 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.708C>A p.Y236* 7
33 COSM10992 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.844C>G p.R282G 7
34 COSM10768 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.535C>T p.H179Y 7
35 COSM10648 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.524G>A p.R175H 7
36 COSM43714 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.836G>A p.G279E 7
37 COSM10645 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.527G>T p.C176F 7
38 COSM10812 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.722C>T p.S241F 7
39 COSM10660 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.818G>A p.R273H 7
40 COSM45607 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.676G>A p.G226S 7
41 COSM45794 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.421T>G p.C141G 7
42 COSM44233 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.840A>C p.R280S 7
43 COSM10905 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.451C>T p.P151S 7
44 COSM10738 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.542G>A p.R181H 7
45 COSM10739 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.481G>A p.A161T 7
46 COSM44220 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.417G>T p.K139N 7
47 COSM45077 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.390C>T p.L130L 7
48 COSM10654 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.637C>T p.R213* 7
49 COSM44218 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.536A>C p.H179P 7
50 COSM10672 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.577C>T p.H193Y 7

Copy number variations for Oral Cancer from CNVD:

7 (show top 50) (show all 92)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 16000 1 120982663 144003083 Loss Oral cancer
2 18683 1 147134204 147499075 Loss Oral cancer
3 22566 1 167493797 167507911 Loss NME7 Oral cancer
4 25915 1 195026732 195048237 Gain Oral cancer
5 25916 1 195026732 195104236 Gain Oral cancer
6 30920 1 246713386 246852155 Loss Oral cancer
7 35162 1 604268 4312064 Gain Oral cancer
8 41154 10 138235 42150788 Loss Oral cancer
9 42635 10 37475290 37508431 Loss Oral cancer
10 43408 10 46396192 46516611 Loss Oral cancer
11 48616 11 101407278 102165885 Gain Oral cancer
12 49060 11 102611683 110151240 Loss Oral cancer
13 50726 11 119044645 133316524 Loss Oral cancer
14 52672 11 186966 2789993 Gain Oral cancer
15 55431 11 52900000 134452384 Gain Oral cancer
16 56752 11 60970713 78077527 Gain Oral cancer
17 58595 11 68654476 70150073 Gain Oral cancer
18 79103 13 6365 44752 Loss Oral cancer
19 82813 14 15600000 106368585 Gain Oral cancer
20 83220 14 19560721 22142166 Gain Oral cancer
21 83591 14 21538460 22005864 Gain Oral cancer
22 85535 14 48265939 80627188 Gain Oral cancer
23 88199 14 87604117 106349785 Gain Oral cancer
24 89600 15 18741744 19805989 Loss Oral cancer
25 89601 15 18741744 20060090 Gain Oral cancer
26 101423 16 36766 2592859 Gain Oral cancer
27 106087 16 85963377 88690615 Gain Oral cancer
28 118416 17 77385789 78462808 Gain Oral cancer
29 120365 18 24990733 76110993 Loss Oral cancer
30 124096 19 1 28500000 Gain Oral cancer
31 127007 19 232109 258746 Gain Oral cancer
32 133960 19 8275 236875 Loss Oral cancer
33 136827 2 133504494 133812256 Loss NCKAP5 Oral cancer
34 144179 2 242501268 242717042 Gain Oral cancer
35 150414 20 1 27100000 Gain Oral cancer
36 151218 20 18609 5869816 Gain Oral cancer
37 151741 20 24728423 25680524 Gain Oral cancer
38 152139 20 29436566 62363603 Gain Oral cancer
39 155361 20 55096989 59483462 Gain Oral cancer
40 155973 20 59483462 62194881 Gain Oral cancer
41 160312 22 134684 14797037 Loss Oral cancer
42 164561 22 37689087 37715408 Loss Oral cancer
43 166146 3 1 91700000 Deletion Oral cancer
44 166162 3 1 91700000 Loss Oral cancer
45 167591 3 121355348 144551988 Gain Oral cancer
46 169747 3 145187343 199379595 Gain Oral cancer
47 171086 3 163941201 164138371 Loss Oral cancer
48 172647 3 185019156 185896384 Gain Oral cancer
49 175342 3 39095 9150490 Loss CHL1 Oral cancer
50 175343 3 39095 9150490 Loss GRM7 Oral cancer

Expression for Oral Cancer

Search GEO for disease gene expression data for Oral Cancer.

Pathways for Oral Cancer

Pathways related to Oral Cancer according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.34 CASP3 CCND1 EGFR MMP2 MMP9 PTGS2
2
Show member pathways
13.01 CASP3 CCND1 CDH1 CDKN2A EGFR MMP9
3
Show member pathways
12.77 CYP1A1 GSTM1 GSTM3 GSTT1 PTGS2
4
Show member pathways
12.64 CCND1 CDH1 CDKN2A EGFR GSTM1 GSTM3
5
Show member pathways
12.57 CCND1 CDKN2A EGFR MMP2 MMP9 TP53
6
Show member pathways
12.54 CASP3 CCND1 MMP9 PTGS2 TP53
7 12.48 CASP3 CCND1 CDKN2A EGFR MMP9 PTGS2
8
Show member pathways
12.47 CASP3 CDH1 EGFR TP53
9
Show member pathways
12.33 CASP3 CCND1 CDKN2A TP53
10 12.33 CCND1 CDH1 CDKN2A TP53
11 12.26 CASP3 CCND1 CDKN2A TP53
12 12.26 CASP3 CCND1 EGFR MMP2 MMP9 TP53
13 12.16 CASP3 CCND1 CDH1 CDKN2A EGFR GSTM1
14 12.13 CASP3 CCND1 CDH1 EGFR TP53
15
Show member pathways
12.12 CCND1 CDKN2A EGFR TP53
16 12.05 GSTM1 GSTM3 GSTT1 MMP2 MMP9 TP53
17 11.98 CASP3 CCND1 CDH1 EGFR MMP2 MMP9
18 11.97 CCND1 MMP2 MMP9 PTGS2 TP53
19 11.95 CCND1 CDKN2A EGFR TP53
20 11.92 CASP3 CCND1 EGFR MMP9 PTGS2 TP53
21 11.86 CASP3 CCND1 PTGS2 RARB TP53
22 11.81 MMP2 MMP9 PTGS2
23 11.79 CCND1 CDH1 MMP2 MMP9
24
Show member pathways
11.75 CYP1A1 GSTM1 GSTT1
25 11.74 CCND1 GSTM1 PTGS2
26 11.7 CASP3 EGFR MMP2 MMP9
27 11.69 CASP3 EGFR MMP2 MMP9
28
Show member pathways
11.66 CCND1 MMP2 MMP9 PTGS2
29 11.65 EGFR SLC7A5 TP53
30 11.62 EGFR MMP2 MMP9
31
Show member pathways
11.6 CCND1 EGFR MMP2 MMP9
32 11.6 CASP3 CDKN2A GSTM1 GSTM3 GSTT1 TP53
33 11.59 CASP3 MMP9 PTGS2
34 11.56 CASP3 CCND1 TP53
35 11.54 CASP3 CCND1 PTGS2 TP53
36 11.51 CCND1 CDKN2A EGFR MMP2 TP53
37 11.5 CYP1A1 EGFR PTGS2
38 11.49 CYP1A1 EGFR SLC7A5
39 11.36 CCND1 CDH1 CDKN2A EGFR MMP2 MMP9
40 11.34 KRT19 PTGS2 TP53
41 11.32 CCND1 MMP2 MMP9
42 11.15 CYP1A1 GSTM1 GSTT1

GO Terms for Oral Cancer

Biological processes related to Oral Cancer according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.99 CASP3 EGFR MMP9 PTGS2 RARB TP53
2 positive regulation of protein phosphorylation GO:0001934 9.87 CCND1 CDK2AP1 EGFR MMP9
3 liver development GO:0001889 9.79 CCND1 CYP1A1 EGFR
4 extracellular matrix disassembly GO:0022617 9.79 CDH1 MMP2 MMP9
5 response to estrogen GO:0043627 9.77 CCND1 GSTM3 KRT19
6 response to glucocorticoid GO:0051384 9.77 CASP3 CCND1 PTGS2
7 glutathione metabolic process GO:0006749 9.75 GSTM1 GSTM3 GSTT1
8 cellular response to heat GO:0034605 9.73 ANO1 PTGS2 TP53
9 positive regulation of apoptotic process GO:0043065 9.73 CASP3 CDKN2A MMP9 PTGS2 RARB TP53
10 embryo implantation GO:0007566 9.71 MMP2 MMP9 PTGS2
11 response to estradiol GO:0032355 9.71 CASP3 CCND1 EGFR PTGS2
12 response to organonitrogen compound GO:0010243 9.7 CCND1 PTGS2 TP53
13 cellular response to reactive oxygen species GO:0034614 9.67 EGFR MMP9 TP53
14 response to drug GO:0042493 9.63 CASP3 CCND1 CDH1 CYP1A1 PTGS2 TP53
15 replicative senescence GO:0090399 9.62 CDKN2A TP53
16 mitotic G1 DNA damage checkpoint GO:0031571 9.61 CCND1 TP53
17 response to antibiotic GO:0046677 9.61 CASP3 CYP1A1 TP53
18 xenobiotic catabolic process GO:0042178 9.58 GSTM1 GSTM3
19 nitrobenzene metabolic process GO:0018916 9.55 GSTM1 GSTM3
20 response to X-ray GO:0010165 9.54 CASP3 CCND1 TP53
21 glutathione derivative biosynthetic process GO:1901687 9.5 GSTM1 GSTM3 GSTT1
22 response to UV-A GO:0070141 9.48 CCND1 EGFR
23 cellular detoxification of nitrogen compound GO:0070458 9.46 GSTM1 GSTM3
24 response to organic substance GO:0010033 9.35 CASP3 CCND1 CDH1 CYP1A1 PTGS2
25 response to organic cyclic compound GO:0014070 9.1 CASP3 CCND1 CYP1A1 EGFR PTGS2 TP53

Molecular functions related to Oral Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein complex binding GO:0032403 9.67 CASP3 CCND1 KRT19 RARB
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.32 CASP3 CDKN2A
3 glutathione binding GO:0043295 9.26 GSTM1 GSTM3
4 enzyme binding GO:0019899 9.17 CCND1 CYP1A1 EGFR GSTM1 GSTM3 PTGS2
5 glutathione transferase activity GO:0004364 9.13 GSTM1 GSTM3 GSTT1
6 protein binding GO:0005515 10.09 ANO1 CASP3 CCND1 CDH1 CDK2AP1 CDKN2A

Sources for Oral Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....